A phase II randomized study of OSI-774 [erlotinib] in African American patients with advanced and previously treated non-small cell lung cancer (NSCLC).

Trial Profile

A phase II randomized study of OSI-774 [erlotinib] in African American patients with advanced and previously treated non-small cell lung cancer (NSCLC).

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Nov 2014

At a glance

  • Drugs Erlotinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 29 Apr 2014 Primary endpoint 'Disease-control-rate' has been met.
    • 29 Apr 2014 Results published in the Clinical Pharmacology and Therapeutics.
    • 01 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top